|
There has been an increase in the number of settings in which outcomes research and Health Economic information have been critical to the development and commercialization of medical technologies. We pride ourselves on our record of supporting optimum price and best positioning within evidence-based clinical guidelines and Health Technology guidance. With the input of our HTA and Pricing and Reimbursement Advisory Boards our Market Access team has a unique insight into recent methodological developments and the
evolution of local pricing and reimbursement policies.
At Mapi Values, our approach to market access consists of a step-wise process to ensure that a product has every chance of getting to market and then becoming established. In short, this comprises:
- Planning outcomes and evidence generation strategies that optimize price, reimbursement and formulary access decisions
-
Competitor reviews
-
Evidence synthesis (meta-analysis)
-
Indirect treatment comparisons and comparative effectiveness
-
Utility studies
-
Cost-effectiveness analysis
-
Burden of disease, cost of illness and database analysis
-
Piggyback studies alongside clinical trials
-
Workshops on indirect treatment comparisons, value of information analysis and direct utility assessment
-
Global value dossiers and country specific reimbursement, pricing and HTA dossiers
-
Reimbursement/HTA submissions (e.g. NICE, SMC, CVZ)
-
Post launch market access support
|
PRO OFFERINGS
EMAIL / 
PRINT / 
SHARE